Abstract: This disclosure is directed to devices, systems, and techniques for a medical device to securely communicate with an external device. The medical device may establish a secure communications channel over a wireless connection with an external device. The medical device may negotiate with the external device via the secure communications channel one or more encryption keys. The medical device may encrypt communications via the wireless communication with the external device using the one or more encryption keys.

Abstract: An internal controller implantable within the body of a patient as part of a left ventricular assist device (LVAD) system and a method therefore are provided. According to one aspect, the internal controller includes processing circuitry configured to establish a radio frequency (RF) communication session with a first external power transmitter that responds to the advertisement. The processing circuitry is also configured to determine when a power transmission status of the first external power transmitter does not match a power receipt status of the internal controller, and then terminate the RF communication session with the first external power transmitter and cause the radio interface to broadcast another advertisement.

Abstract: An internal controller implantable within the body of a patient as part of a left ventricular assist device (LVAD) system and a method therefore are provided. According to one aspect, the internal controller includes processing circuitry configured to establish a radio frequency (RF) communication session with a first external power transmitter that responds to the advertisement. The processing circuitry is also configured to determine when a power transmission status of the first external power transmitter does not match a power receipt status of the internal controller, and then terminate the RF communication session with the first external power transmitter and cause the radio interface to broadcast another advertisement.

Abstract: Fas ligand (CD95L) induces apoptosis in activated T cells through the process of Activation Induced Cell Death (AICD). Gelatin nanoparticles are virus sized gelatin-protein-DNA complexes which can encapsulate multiple DNA vectors and proteins, and which are thought to act by increasing in vivo transfection of antigen presenting cells. By injecting mice with gelatin nanoparticles containing a murine Fas ligand (CD95L) DNA vector and a &bgr;-galactosidase (LacZ) model antigen vector, the T cell response specific for &bgr;-gal was ablated without effecting the response to a secondary antigen. In effect, this “tolerization” injection induced antigen specific peripheral tolerance in study mice, and is applicable to the treatment of autoimmune diseases when self-antigens such as Myelin Basic Protein are co-delivered with the fas ligand.